CURRENT STATUS AND PROGRESS OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN GASTRIC CANCER: A LITERATURE REVIEW

Shantanu Baral, Mubeen Hussein Arawker, Qiannan Sun and Daorong Wang*

ABSTRACT

Patients with metachronous peritoneal metastasizing gastric cancer show poor prognosis. Despite potentially curative treatment, gastric cancer survival remains low, primarily due to metastasizing recurrence. To prolong the survival rate and reduce the recurrence rate after radical resection of gastric cancer has become a focal point in the diagnosis and treatment of gastric cancer. Hyperthermic intraperitoneal chemotherapy has a good effect on the prevention and treatment of postoperative recurrence of gastric cancer and advanced malignant ascites. We review the current status of HIPEC in gastric cancer in terms of mechanisms, drug selection, prophylactic and therapeutic HIPEC, and biomarkers related to prognosis.

Keywords: Gastric cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal perfusion chemotherapy.